Skip to main content
Terug
Watch Compare

Werewolf Therapeutics, Inc.

Datakwaliteit: 83%
HOWL
Nasdaq Manufacturing Chemicals
€ 0,90
▼ € 0,08 (-8,21%)
Marktkapitalisatie: 43,91 M
Prijs
€ 0,90
Marktkapitalisatie
43,91 M
Dagbereik
€ 0,88 — € 0,98
52-Weeksbereik
€ 0,53 — € 2,38
Volume
184.873
Openen € 0,98
50D / 200D Gem.
€ 0,73
24,46% above
50D / 200D Gem.
€ 1,10
17,70% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -60,29 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-171,14%
Onder sectorgemiddelde (-51,02%)
ROIC-68,76%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
1,08
Boven sectorgemiddelde (0,33)
Current Ratio3,87
Interest Coverage-11,50

Waardering

PE (TTM)
-0,72
Boven sectorgemiddelde (-1,98)
P/B Ratio1,48
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -0,7 -2,0
P/B 1,5 5,1
ROE % -171,1 -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E 1,1 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -60,82 M
ROE -171,14% ROA -70,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -60,29 M
ROIC -68,76% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,08 Current Ratio 3,87
Interest Coverage -11,50 Asset Turnover N/A
Working Capital 50,57 M Tangible Book Value 29,61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,72 Forward P/E N/A
P/B Ratio 1,48 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -137,30%
Market Cap 43,91 M Enterprise Value 10,29 M
Per Share
EPS (Diluted TTM) -1,33 Revenue / Share N/A
FCF / Share -1,24 OCF / Share -1,24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 99,13%
SBC-Adj. FCF -67,34 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -60,82 M -70,52 M -37,37 M -53,81 M -49,98 M
EPS (Diluted) -1,33 -1,63 -1,05 -1,86 -10,94
Gross Profit — — — — —
Operating Income -60,68 M -73,59 M -40,50 M -56,06 M -50,09 M
EBITDA — — — — —
R&D Expenses 44,83 M 56,43 M 41,78 M 53,76 M 35,27 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5,27 M 3,31 M 3,14 M — —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 69,40 M 126,93 M 174,83 M 160,25 M 179,25 M
Total Liabilities 44,59 M 53,54 M 63,46 M 37,91 M 26,46 M
Shareholders' Equity 24,81 M 73,39 M 111,37 M 122,34 M 152,79 M
Total Debt 32,09 M 32,09 M 40,00 M — —
Cash & Equivalents 57,05 M 111,00 M 134,34 M 129,32 M 157,53 M
Current Assets 58,59 M 113,07 M 138,37 M 140,20 M 161,07 M
Current Liabilities 36,15 M 15,18 M 19,38 M 23,99 M 11,87 M